These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16611151)

  • 1. The management of phosphodiesterase-5 (PDE5) inhibitor failure.
    Lau DH; Kommu S; Mumtaz FH; Morgan RJ; Thompson CS; Mikhailidis DP
    Curr Vasc Pharmacol; 2006 Apr; 4(2):89-93. PubMed ID: 16611151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future options for combination therapy in the management of erectile dysfunction in older men.
    Sommer F; Engelmann U
    Drugs Aging; 2004; 21(9):555-64. PubMed ID: 15260511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent insights into androgen action on the anatomical and physiological substrate of penile erection.
    Gooren LJ; Saad F
    Asian J Androl; 2006 Jan; 8(1):3-9. PubMed ID: 16372114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
    Sommer F; Schulze W
    World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.
    Archer SL; Gragasin FS; Webster L; Bochinski D; Michelakis ED
    Drugs Aging; 2005; 22(10):823-44. PubMed ID: 16245957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.
    Seftel AD
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I14-19. PubMed ID: 15115191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats.
    Wilkes N; White S; Stein P; Bernie J; Rajasekaran M
    Int J Impot Res; 2004 Apr; 16(2):187-94. PubMed ID: 15073608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
    Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
    Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
    Küthe A; Montorsi F; Andersson KE; Stief CG
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
    de Tejada IS
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.